A detailed history of Sheets Smith Investment Management transactions in Bio Atla, Inc. stock. As of the latest transaction made, Sheets Smith Investment Management holds 67,000 shares of BCAB stock, worth $45,560. This represents 0.03% of its overall portfolio holdings.

Number of Shares
67,000
Holding current value
$45,560
% of portfolio
0.03%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 08, 2025

BUY
$0.33 - $0.77 $22,110 - $51,590
67,000 New
67,000 $46,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $24.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Sheets Smith Investment Management Portfolio

Follow Sheets Smith Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheets Smith Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Sheets Smith Investment Management with notifications on news.